MedTrace Logo

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

NCT00407095 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2010-09-13

No results posted yet for this study

Summary

This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.

Conditions

  • Advanced Stage Parkinson's Disease

Interventions

DRUG

Pardoprunox

12-42 mg/day

Sponsors & Collaborators

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Erik Vanleeuwen · Abbott Products

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-08-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States
  • Albania
  • Argentina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • Colombia
  • Latvia
  • Lithuania
  • Peru
  • Russia
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407095 on ClinicalTrials.gov